Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00800904
First received: December 1, 2008
Last updated: December 2, 2010
Last verified: December 2010
  Purpose

The purpose of this study is to determine the percentage of patients who has reached the GINA guideline of asthma treatment after receiving any inhaled corticosteroid for 3 months or longer in actual clinical practice. Such percentage for each level of severity - mild, moderate and severe persistent asthma as well as the differences of these rates will also be explored.


Condition
Asthma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Asthma Control Among Patients Who Were Receiving Inhaled Corticosteroids in General Practice in Thailand

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Asthma control test [ Time Frame: On the survey date ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Asthma control in mild, moderate and severe persistent asthma patients [ Time Frame: On the survey date ] [ Designated as safety issue: No ]

Estimated Enrollment: 1210
Study Start Date: May 2009
Study Completion Date: November 2009
  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patient aged 12 years and older who established persistent asthma and currently treated with any inhaled corticosteroid for 3 months or longer.

Criteria

Inclusion Criteria:

  • Established persistent asthma
  • Currently treated with any inhaled corticosteroid therapy but not SYMBICORT nor SERETIDE for 3 months or longer

Exclusion Criteria:

  • Currently participating or have participated in a study with an investigational compound within the last 30 days
  • Current diagnosis of chronic obstructive pulmonary disease (COPD)
  • Smoked more than 10 packs a year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00800904

Locations
Thailand
Research Site
Amnat Charoen, Thailand
Research Site
Buriram, Thailand
Research Site
Chachoengsao, Thailand
Research Site
Chaiyaphum, Thailand
Research Site
Chanthaburi, Thailand
Research Site
Chiang Rai, Thailand
Research Site
Kalasin, Thailand
Research Site
Khon Kaen, Thailand
Research Site
Lopburi, Thailand
Research Site
Mae Hong Son, Thailand
Research Site
Mahasarakham, Thailand
Research Site
Nakhon Phanom, Thailand
Research Site
Nakhorn Ratchasima, Thailand
Research Site
Nan, Thailand
Research Site
Nong Khai, Thailand
Research Site
Samutsongkhram, Thailand
Research Site
Si Sa Ket, Thailand
Research Site
Singburi, Thailand
Research Site
Songkla, Thailand
Research Site
Sukhothai, Thailand
Research Site
Surat Thani, Thailand
Research Site
Trang, Thailand
Research Site
Trat, Thailand
Research Site
Ubon Ratchathani, Thailand
Research Site
Udon Thani, Thailand
Research Site
Yasothon, Thailand
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Bandit Thinkhamrop, PhD Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University
Principal Investigator: Watchara Boonsawat, MD. PhD Department of Medicine, Faculty of Medicine, Khon Kaen University
  More Information

No publications provided

Responsible Party: Thanu Komolsai, MD, Medical Advisor, AstraZeneca (Thailand) Ltd.
ClinicalTrials.gov Identifier: NCT00800904     History of Changes
Other Study ID Numbers: NIS-RTH-DUM-2008/1
Study First Received: December 1, 2008
Last Updated: December 2, 2010
Health Authority: Thailand: Ethical Committee

Keywords provided by AstraZeneca:
Asthma
Inhaled corticosteroid
Thai patient eligibility
Persistent asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on October 02, 2014